Drug Watch

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.

Late-breaking data shared at AAD 2026 supports oral TYK2 envudeucitinib's efficacy and safety in moderate-to-severe plaque psoriasis.

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.

The upcoming trial will assess an injectable formulation of Xvie, distinct from its currently available topical counterpart.

Phase 2 APEX part A data showed zumilokibart maintained EASI-75 responses in 75–85% of week 16 responders at 1 year across quarterly and biannual dosing regimens.

Only 15–20% of eligible patients currently receive systemic psoriasis treatment, and specialists believe icotrokinra's simplicity could meaningfully move that needle.

Clinical trial data showed approximately 70% of patients achieved clear or almost clear skin with icotrokinra by week 16.

Sun Pharma's tildrakizumab nears psoriatic arthritis approval as FDA accepts a supplemental biologics license application (sBLA), spotlighting IL-23 benefits for active disease.

Positive phase 3 findings from ADorable-1 suggest lebrikizumab could expand biologic treatment options for younger patients with atopic dermatitis (AD).

Novartis secured the approval through a pharmacokinetic extrapolation strategy rather than a full pediatric RCT, leveraging adult HS trial data and existing pediatric PK modeling from other approved indications.

Results show that bimekizumab achieved significantly higher ACR50 response rates at week 16 than risankizumab in adults with active PsA.

FDA Fast Track boosts hopes for QRX003 lotion in Netherton Syndrome, with early trials showing rapid skin healing and itch relief.

Patients treated with deucravacitinib achieved higher ACR20 response rates at week 16 than those receiving placebo in the POETYK PsA studies.

Clearance rates increased between days 29 and 57, with the highest activity observed in the 200-μg treatment group.

Rocatinlimab had met primary end points in large phase 3 trials and was previously expected to move toward regulatory submission in 2026.

Priovant Therapeutics' brepocitinib has been assigned a Prescription Drug User Fee Act date in the third quarter of 2026.

The double-blind, randomized, placebo-controlled ARQ-234-131 study will assess safety, tolerability, pharmacokinetics, and early signs of clinical activity.

After TMB-001 did not meet its primary end point in the ASCEND trial, LEO Pharma moved to out-license the vehicle formulation, which unexpectedly provided a response in 40% of patients.

Over 70% of evaluable patients achieved near-clear or clear skin after nearly 3 years of treatment with nemolizumab.

Barzolvolimab is a humanized monoclonal antibody that inhibits the KIT receptor, aiming to reduce mast cell survival and activity in chronic spontaneous urticaria.

In a 52-week phase 3 study, CT-P43 demonstrated sustained efficacy comparable to reference ustekinumab in adults with moderate to severe plaque psoriasis.

Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients.

Neal Bhatia, MD, explores denifanstat for acne—oral FASN inhibition that curbs sebum, boosts outcomes, and may be an alternative to antibiotics or retinoids.

BEACON phase 2 shows brepocitinib delivers dramatic, low-placebo CSAMI improvements with strong safety, Misha Rosenbach, MD reports, boosting hope for cutaneous sarcoidosis.

In the phase 3b TOGETHER-PsO trial, ixekizumab plus tirzepatide led to significantly higher rates of complete skin clearance and ≥10% weight loss.